Immunotherapy Strategies for Head and Neck Squamous Cell Carcinoma: Present Practices and Future Perspectives
-
By
-
Carol R. Bradford
-
Sreeram M. P.
-
Karthik N. Rao
-
Orlando Guntinas-Lichius
-
Nabil Saba
-
Alfio Ferlito
-
July 9, 2026
Clinical Scorecard: Immunotherapy Strategies for Head and Neck Squamous Cell Carcinoma: Present Practices and Future Perspectives
At a Glance
| Category | Detail |
|---|
| Condition | Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Key Mechanisms | Immune checkpoint inhibitors, particularly PD-1 inhibitors, enhance the immune response against cancer cells. |
| Target Population | Patients with recurrent, metastatic, and locally advanced HNSCC. |
| Care Setting | Oncology clinics and hospitals providing cancer treatment. |
Key Highlights
- PD-1 inhibitors like nivolumab and pembrolizumab show efficacy in advanced HNSCC.
- Clinical trials demonstrate improved overall survival with pembrolizumab compared to standard chemotherapy.
- Nivolumab and pembrolizumab have favorable safety profiles with lower rates of severe adverse events.
Guideline-Based Recommendations
Diagnosis
- Assess PD-L1 expression as a predictive biomarker for response to PD-1 inhibitors.
Management
- Use pembrolizumab as a first-line treatment for PD-L1-positive R/M HNSCC.
Monitoring & Follow-up
- Monitor for treatment-related adverse events, particularly pneumonitis.
Risks
- Potential for Grade 3 or 4 treatment-related adverse events, including pulmonary toxicity.
Patient & Prescribing Data
Patients with recurrent or metastatic HNSCC, including both HPV-positive and HPV-negative tumors.
Responses to PD-1 inhibitors can be durable, with some lasting over a year.
Clinical Best Practices
- Consider the timing of immunotherapy administration (concurrent vs. sequential).
- Integrate immunotherapy with existing standard of care modalities.
Related Resources & Content
